Suzhou industrial park yuan venture capital investment management co., ltd ( yuan venture capital ) focuses on the early-stage venture investment in the field of life science, the investment object is with the high strength growth, the larger development space, the management team excellent biotechnology, new drug research and development, medical devices and medical and health services companies, and provides funds, management, operation, and other aspects of support and services. The two - stage RMB fund of yuan venture capital has a total scale of about RMB hundred million, and has completed the investment of 34 high quality projects. Through dedicated and rich industry resources, yuan venture capital aspires to become one of the most successful venture capital investment funds in China.
And capital is an excellent venture capital firm rooted in the Chinese market, focusing on innovative investment opportunities in the life sciences and health care industry. Bio participates as a limited partner and promotes the growth and development of innovative Chinese biomedical enterprises. The industry focus of the fund focuses on the technology and platform closely related to the life science in the emerging strategic industries supported by the state. And capital under its current management of the renminbi and the us dollar two parallel funds, to our attention to the financing needs of enterprises to provide more structural flexibility.
The Suzhou golden pebble biological venture capital fund is a specialized fund set up by bio and citic securities co., ltd, the main investment direction is biological medicine, medical equipment, gene industry and other fields in the early stage of industrialization and quasi - listed enterprises. The total scale of the fund is RMB 10, with a period of RMB 300 million, taking Suzhou industrial park as the core gradually radiating the whole country, relying on the comprehensive strength of citic securities and bio, through the linkage of investment and listing, making city business, make the fund become a professional investment force matching the brand and income of Suzhou industrial park.
Medtronic China fund was established in 2016, the first phase of the fund is mainly the American Medtronic medical group, sequoia capital and Suzhou biological nano - company, focusing on the Chinese regional medical equipment, disease management and other life sciences equity investment. The fund team is composed of experienced health investment, product development and market sales professionals, and discovers and invests potential enterprises to help them grow into a leading enterprise in the segmentation area.
For more information, please click
The innovative ecological circle of the most capital concern in China
Two domestic enterprises are included in Top 10 Young Companies in the Money of 2016.
Cinda organisms （）
Enterprises in the park raised nearly RMB9 billion in 2016.